Neurona will kick start a Phase III trial in H2 2025 investigating NRTX-1001 in patients with a type of drug-resistant ...

Sanofi's reversible BTK inhibitor rilzabrutinib has gained the US Food and Drug Administration’s (FDA) orphan drug ...

Roche outlined how digital health technologies (DHTs) provide more sensitive measures of disease progression in early ...

Streeting said his June 10-year plan will address drug sale clawbacks, NICE regulation, and the abolition of NHS England.

Boehringer Ingelheim subsidiary NBE Therapeutics has opened its new antibody-drug conjugates (ADC) R&D facility in Basel, ...

Astellas Pharma has entered a strategic partnership with the JFCR to expedite research in translational and clinical oncology ...

Late-stage pipeline products anticipated to reach the uveitis market during the forecast period will introduce new mechanisms ...

If preclinical findings were translated into the clinic, they could shorten the CAR-T generation lead time from two weeks to ...

Atsena Therapeutics has completed an oversubscribed Series C financing round, raising $150m to support the advancement of ...

According to a factsheet published by the Trump administration, pharmaceuticals are exempted from the tariffs – for now.

The EC has approved Daiichi Sankyo and AstraZeneca’s Enhertu for use as a single agent to treat adults with certain breast ...

This week, the Trump administration followed through on its planned mass layoffs at agencies under the US Department of ...